Tvardi Therapeutics, Inc. (TVRD) shareholders
Close on Nov 17, 2026Market cap $13.47MP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vifor (International) Ltd. Joint filing with CSL Limited (13.50%) | 7,396,770 | 13.50% | 13D (active) amendment | Dec 17, 2024 |
| Sporos Bioventures LLC | 837,636 | 8.95% | 13G (passive) | Apr 15, 2025 |
| Solas Partners II, LLC Joint filing with Solas Tvardi Sidecar LLC (8.10%), Solas BioVentures Fund II, LP (8.10%) | 761,287 | 8.10% | 13G (passive) | Apr 15, 2025 |
| Slate Path Capital LP Joint filing with David Greenspan (7.50%) | 704,118 | 7.50% | 13G (passive) | Jun 30, 2025 |
| David J. Tweardy | 652,398 | 7.00% | 13G (passive) | Apr 15, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TVRD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Slate Path Capital LP | 704,118 | 5.28% | $1.34M | – | 0.02% |
| Vanguard Capital Management LLC | 344,382 | 2.58% | $654.33K | −326 | 0.00% |
| American Financial Group Inc | 223,659 | 1.68% | $424.95K | – | 0.15% |
| UBS Group AG | 111,133 | 0.83% | $211.15K | +60,679 | 0.00% |
| Silvercrest Asset Management Group LLC | 101,034 | 0.76% | $191.97K | – | 0.00% |
| BlackRock, Inc. | 95,478 | 0.72% | $181.41K | −292,597 | 0.00% |
| Renaissance Technologies LLC | 91,409 | 0.69% | $173.68K | −691 | 0.00% |
| Geode Capital Management, LLC | 90,350 | 0.68% | $171.74K | −91,989 | 0.00% |
| Morgan Stanley | 77,845 | 0.58% | $147.91K | +4,951 | 0.00% |
| Duncan Williams Asset Management, LLC | 63,241 | 0.47% | $120.16K | – | 0.03% |
| Vanguard Fiduciary Trust Co | 44,710 | 0.34% | $84.95K | −2,162 | 0.00% |
| Russell Investments Group, Ltd. | 43,228 | 0.32% | $82.13K | +19,921 | 0.00% |
| State Street Corp | 33,900 | 0.25% | $64.41K | −63,331 | 0.00% |
| Susquehanna International Group, Llp | 33,165 | 0.25% | $63.01K | New | 0.00% |
| Aqr Capital Management LLC | 27,096 | 0.20% | $51.48K | −15,096 | 0.00% |
| Northern Trust Corp | 21,836 | 0.16% | $41.49K | −27,245 | 0.00% |
| Savant Capital, LLC | 19,462 | 0.15% | $49.43K | New | 0.00% |
| Gsa Capital Partners Llp | 17,885 | 0.13% | $34.00K | New | 0.00% |
| Diadema Partners LP | 16,607 | 0.12% | $31.55K | New | 0.00% |
| XTX Topco Ltd | 14,868 | 0.11% | $28.25K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 58 | 2M | 16.7% | 13 / 7 | 24 / 20 | 0M | 1M |
| Q1 2026 | 67 | 3M | 20.3% | 16 / 19 | 17 / 11 | 1M | 0M |
| Q4 2025 | 64 | 3M | 21.2% | 14 / 28 | 7 / 15 | 1M | 1M |
| Q3 2025 | 65 | 3M | 19.5% | 23 / 21 | 6 / 7 | 1M | 0M |
| Q2 2025 | 49 | 2M | 14.4% | 49 / 0 | 0 / 0 | 2M | 0M |
| Q1 2025 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q4 2024 | 1 | 0M | 0.1% | 0 / 1 | 0 / 68 | 0M | 0M |
| Q3 2024 | 70 | 0M | 2.8% | 7 / 5 | 33 / 16 | 0M | 0M |
| Q2 2024 | 81 | 0M | 3.7% | 16 / 15 | 24 / 36 | 0M | 0M |
| Q1 2024 | 101 | 1M | 5.0% | 13 / 24 | 33 / 24 | 0M | 0M |
| Q4 2023 | 112 | 1M | 5.1% | 18 / 31 | 33 / 29 | 0M | 0M |
| Q3 2023 | 124 | 1M | 5.6% | 17 / 35 | 40 / 30 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
65 funds held TVRD in Q1 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TVRD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 258,426 | 1.94% | $491.01K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 85,956 | 0.64% | $163.32K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 50,517 | 0.38% | $170.75K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 30,558 | 0.23% | $103.29K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 14,439 | 0.11% | $48.80K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 12,181 | 0.09% | $41.17K | 0.00% | May 31, 2026 |
| iShares Russell 2000 ETF | 8,873 | 0.07% | $16.86K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 6,450 | 0.05% | $21.80K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Value Index Fund | 3,820 | 0.03% | $12.91K | 0.00% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 2,607 | 0.02% | $4.95K | 0.00% | Jun 30, 2026 |
| Bridge Builder Small/Mid Cap Value Fund | 1,975 | 0.01% | $3.75K | 0.00% | Jun 30, 2026 |
| Small Cap Index Fund | 1,388 | 0.01% | $4.69K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 1,225 | 0.01% | $2.33K | 0.00% | Jun 30, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 471 | 0.00% | $1.59K | 0.00% | May 31, 2026 |
| Master Small Cap Index Series | 402 | 0.00% | $764 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Imran Nizamudin Alibhai | Chief Executive Officer, Director | – | – | Feb 2, 2026 |
| Christopher Posner | PRESIDENT AND CEO, Director | 13,109 | 0.10% | Mar 4, 2025 |
| Avi Daniel Conn | Chief Financial Officer | – | – | Feb 2, 2026 |
| John Saewook M.D. Kauh | Chief Medical Officer | – | – | Feb 2, 2026 |
| Stephen Paul O'Brien | Principal Accounting Officer | – | – | Feb 2, 2026 |
| Yixin Chen | VP, Chem, Mfg and Ctrls | – | – | Apr 21, 2025 |
| Jeffrey Leroy Larson | SVP, Research & Development | – | – | Apr 21, 2025 |
| Scott Terrillion | SEC'Y; CHIEF COMPLIANCE & G.C. | 7,190 | 0.05% | Mar 4, 2025 |
| Michael S. Wyzga | Director | – | – | Jun 11, 2026 |
| Cynthia Smith | Director | – | – | Jun 11, 2026 |
| Susan Ph.D. Shiff | Director | 202,085 | 1.52% | Jun 11, 2026 |
| Wallace L. Hall Jr | Director | 246,756 | 1.85% | Jun 11, 2026 |
| Sujal Shah | Director | – | – | Jun 11, 2026 |
| Shaheen Wirk | Director | 443,385 | 3.32% | May 2, 2025 |
| Samuel David Tweardy | 10% owner | 0 | – | Aug 5, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Samuel David Tweardy 10% owner | Jul 7, 2025 | Other | −315,658 | – | – | 0 |
| Samuel David Tweardy 10% owner | Jul 7, 2025 | Other | −315,658 | – | – | 0 |
| Shaheen Wirk Director | Apr 15, 2025 | Award | +176,030 | – | – | 176,030 |
| Shaheen Wirk Director | Apr 15, 2025 | Award | +263,164 | – | – | 263,164 |
| Wallace L. Hall Jr Director | Apr 15, 2025 | Award | +202,044 | – | – | 202,044 |
| Wallace L. Hall Jr Director | Apr 15, 2025 | Award | +44,712 | – | – | 44,712 |
| Wallace L. Hall Jr Director | Apr 15, 2025 | Other | +44,712 | – | – | 44,712 |
| Wallace L. Hall Jr Director | Apr 15, 2025 | Other | +202,044 | – | – | 202,044 |
| Shaheen Wirk Director | Apr 15, 2025 | Other | +176,030 | – | – | 176,030 |
| Shaheen Wirk Director | Apr 15, 2025 | Other | +263,164 | – | – | 263,164 |
| Shaheen Wirk Director | Apr 15, 2025 | Award | +4,191 | – | – | 4,191 |
| Christopher Posner PRESIDENT AND CEO, Director | Feb 28, 2025 | Sale(10b5-1 plan) | −583 | $4.75 | $2.77K | 13,109 |
| Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. | Feb 28, 2025 | Sale(10b5-1 plan) | −163 | $4.76 | $776 | 7,190 |
| Christopher Posner PRESIDENT AND CEO, Director | Feb 4, 2025 | Sale(10b5-1 plan) | −372 | $4.72 | $1.76K | 13,692 |
| Christopher Posner PRESIDENT AND CEO, Director | Nov 4, 2024 | Sale(10b5-1 plan) | −3,668 | $0.29 | $1.06K | 168,768 |
| Christopher Posner PRESIDENT AND CEO, Director | Aug 1, 2024 | Sale(10b5-1 plan) | −4,149 | $0.35 | $1.45K | 172,436 |
| Moltke Lisa von Director | Jun 4, 2024 | Award | +150,647 | – | – | 183,009 |
| Martin Vogelbaum Director | Jun 4, 2024 | Award | +301,295 | – | – | 411,007 |
| Jeffrey L. Ives Director | Jun 4, 2024 | Award | +150,647 | – | – | 198,485 |
| Helen M. Boudreau Director | Jun 4, 2024 | Award | +150,647 | – | – | 150,647 |
| Susan Ph.D. Shiff Director | Jun 4, 2024 | Award | +150,647 | – | – | 202,085 |
| Christopher Posner PRESIDENT AND CEO, Director | May 2, 2024 | Sale(10b5-1 plan) | −3,936 | $0.75 | $2.95K | 176,585 |
| Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. | Apr 5, 2024 | Sale(10b5-1 plan) | −2,753 | $0.83 | $2.28K | 88,247 |
| Joana Goncalves CHIEF MEDICAL OFFICER | Apr 5, 2024 | Sale(10b5-1 plan) | −2,753 | $0.83 | $2.28K | 53,365 |
| Joana Goncalves CHIEF MEDICAL OFFICER | Feb 29, 2024 | Sale(10b5-1 plan) | −3,293 | $0.89 | $2.93K | 56,118 |
| Christopher Posner PRESIDENT AND CEO, Director | Feb 29, 2024 | Sale(10b5-1 plan) | −5,834 | $0.89 | $5.19K | 180,521 |
| Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. | Feb 29, 2024 | Sale(10b5-1 plan) | −3,293 | $0.89 | $2.93K | 91,000 |
| Christopher Posner PRESIDENT AND CEO, Director | Feb 8, 2024 | Sale(10b5-1 plan) | −35,575 | $0.53 | $18.85K | 186,355 |
| Christopher Posner PRESIDENT AND CEO, Director | Feb 1, 2024 | Sale(10b5-1 plan) | −4,981 | $0.55 | $2.74K | 221,930 |
| Christopher Posner PRESIDENT AND CEO, Director | Feb 1, 2024 | Award | +62,500 | – | – | 226,911 |
| Joana Goncalves CHIEF MEDICAL OFFICER | Feb 1, 2024 | Award | +13,500 | – | – | 67,181 |
| Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. | Feb 1, 2024 | Award | +13,500 | – | – | 102,063 |
| Frederique Ph.D. Menzaghi CHIEF SCIENTIFIC OFF,SVP-R&D | Feb 1, 2024 | Award | +13,500 | – | – | 167,247 |
| Ryan D. Maynard CHIEF FINANCIAL OFFICER | Feb 1, 2024 | Award | +13,500 | – | – | 13,500 |
| Christopher Posner President and CEO, Director | Nov 2, 2023 | Sale(10b5-1 plan) | −3,796 | $1.22 | $4.63K | 164,411 |
| Christopher Posner President and CEO, Director | Aug 3, 2023 | Sale(10b5-1 plan) | −4,307 | $3.07 | $13.22K | 168,207 |
| Frederique Ph.D. Menzaghi Chief Scientific Off,SVP-R&D | Jun 23, 2023 | Sale(10b5-1 plan) | −2,993 | $3.51 | $10.51K | 153,747 |
| Joana Goncalves Chief Medical Officer | Jun 23, 2023 | Sale(10b5-1 plan) | −2,723 | $3.51 | $9.56K | 53,681 |
| Scott Terrillion Sec'y; Chief Compliance & G.C. | Jun 23, 2023 | Sale(10b5-1 plan) | −2,483 | $3.51 | $8.72K | 88,563 |
| Harrison M. Bains Jr Director | Jun 1, 2023 | Award | +32,362 | – | – | 57,438 |
| Susan Ph.D. Shiff Director | Jun 1, 2023 | Award | +32,362 | – | – | 51,438 |
| Martin Vogelbaum Director | Jun 1, 2023 | Award | +64,724 | – | – | 109,712 |
| Jeffrey L. Ives Director | Jun 1, 2023 | Award | +32,362 | – | – | 47,838 |
| Moltke Lisa von Director | Jun 1, 2023 | Award | +32,362 | – | – | 32,362 |
| Christopher Posner President and CEO, Director | May 5, 2023 | Sale(10b5-1 plan) | −3,869 | $4.40 | $17.02K | 172,514 |
| Joana Goncalves Chief Medical Officer | Apr 4, 2023 | Sale(10b5-1 plan) | −2,481 | $4.91 | $12.18K | 56,404 |
| Scott Terrillion Sec'y; Chief Compliance & G.C. | Apr 4, 2023 | Sale(10b5-1 plan) | −2,481 | $4.91 | $12.18K | 91,046 |
| Frederique Ph.D. Menzaghi Chief Scientific Off,SVP-R&D | Apr 4, 2023 | Sale(10b5-1 plan) | −2,733 | $4.91 | $13.42K | 156,740 |
| Frederique Ph.D. Menzaghi Chief Scientific Off,SVP-R&D | Mar 3, 2023 | Sale(10b5-1 plan) | −6,802 | $9.71 | $66.05K | 159,473 |
| Christopher Posner President and CEO, Director | Mar 3, 2023 | Sale(10b5-1 plan) | −5,987 | $9.71 | $58.13K | 176,383 |
| Joana Goncalves Chief Medical Officer | Mar 3, 2023 | Sale(10b5-1 plan) | −6,221 | $9.71 | $60.41K | 58,885 |
| Scott Terrillion Sec'y; Chief Compliance & G.C. | Mar 3, 2023 | Sale(10b5-1 plan) | −6,256 | $9.71 | $60.75K | 93,527 |
| Joana Goncalves Chief Medical Officer | Feb 16, 2023 | Sale(10b5-1 plan) | −2,265 | $10.20 | $23.10K | 65,106 |
| Ryan D. Maynard CHIEF FINANCIAL OFFICER | Feb 8, 2023 | Sale(10b5-1 plan) | −5,488 | $0.53 | $2.91K | 8,012 |
| Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. | Feb 8, 2023 | Sale(10b5-1 plan) | −7,770 | $0.53 | $4.12K | 94,293 |
| Joana Goncalves CHIEF MEDICAL OFFICER | Feb 8, 2023 | Sale(10b5-1 plan) | −7,770 | $0.53 | $4.12K | 59,411 |
| Christopher Posner President and CEO, Director | Feb 2, 2023 | Sale(10b5-1 plan) | −4,191 | $11.80 | $49.45K | 182,370 |
| Joana Goncalves Chief Medical Officer | Jan 17, 2023 | Sale(10b5-1 plan) | −2,265 | $10.81 | $24.48K | 67,371 |
| Joana Goncalves Chief Medical Officer | Dec 29, 2022 | Sale(10b5-1 plan) | −2,265 | $10.18 | $23.06K | 69,636 |
| Frederique Ph.D. Menzaghi Chief Scientific Off,SVP-R&D | Dec 21, 2022 | Sale(10b5-1 plan) | −3,506 | $11.27 | $39.51K | 166,275 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Tvardi Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 22,503 shares on Aug 31, 2026 over the last 90 days.
See a number that looks wrong?